ArticleMaterials advances2026
A CRISPR-Cas12a amplified RNase activity sensor powered by gold nanoparticle-barcode DNA multipliers.
Article in Materials advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ribonuclease A (RNase A) is a clinically relevant biomarker whose aberrant activity compromises RNA stability and interferes with RNA-based therapeutics, highlighting the need for rapid and ultrasensitive detection tools. In this work, we developed a CRISPR/Cas12a-assisted biosensing platform integrated with a substrate-bridged magnetic bead-gold nanoparticle assembly (SB-MAC) for highly sensitive and selective RNase A detection. By optimizing AuNP loading density, RNA substrate/barcode DNA molar ratio, and enzymatic incubation conditions, the prepared dual-functionalized SB-MAC architecture enabled efficient substrate/RNase A cleavage interaction and significant signal amplification, yielding a limit of detection (LOD) of 0.16 pg mL
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.